Medexus Pharmaceuticals Inc.

Total Valuation

Medexus Pharmaceuticals Inc. carries a market capitalization of 105.75M, placing it among publicly traded companies globally. Its enterprise value stands at 181.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Medexus Pharmaceuticals Inc. currently has 31.66M shares outstanding.

Valuation Ratios

Medexus Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 110.65. The price-to-sales ratio is 1.58, and the price-to-book ratio stands at 3.35.

Enterprise Valuation

On an enterprise value basis, Medexus Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 10.81 and an EV/FCF ratio of 5.30. The EV/Sales ratio of 1.76 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.61 provides insight into valuation relative to core operating earnings.

Financial Position

Medexus Pharmaceuticals Inc. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.62, indicating elevated leverage, while an interest coverage ratio of 3.33 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Medexus Pharmaceuticals Inc. has paid -22,000.00 in income taxes, reflecting an effective tax rate of 82.06.

Stock Price Statistics

Medexus Pharmaceuticals Inc.'s stock has gained approximately 62.13592% over the past 52 weeks. The 50-day moving average sits at 3.63, while the 200-day moving average is 2.84.

Income Statement

Over the trailing twelve months, Medexus Pharmaceuticals Inc. generated 103.30M in revenue and converted that into -2.37M in net income, yielding earnings per share of -0.07. EBITDA reached 16.82M, while operating income came in at 7.10M.

Balance Sheet

Medexus Pharmaceuticals Inc. holds 5.34M in cash and equivalents against 26.25M in total debt, resulting in a net debt position of 20.91M. Total book value stands at 48.07M, with working capital of 13.74M providing operational flexibility.

Cash Flow

Medexus Pharmaceuticals Inc. produced 14.23M in operating cash flow over the past twelve months. After subtracting -15.05M in capital expenditures, free cash flow totaled -823,000.00 - equivalent to -0.03 per share.

Margins

Medexus Pharmaceuticals Inc. operates with a gross margin of 54.73, reflecting its pricing power and cost economics. The operating margin of 6.87 and net profit margin of -2.29 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Medexus Pharmaceuticals Inc.'s most recent stock split took place on January 7, 2019 with a 15:1 split ratio.

Scores

Medexus Pharmaceuticals Inc. posts an Altman Z-Score of 1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.